Sanarus Technologies

Sanarus has developed, patented, and tested a proprietary minimally invasive breast therapy system. The Visica 2TMTreatment System is an image-guided cryoablation device for the treatment of breast tumors as an alternative to surgical lumpectomy. This breast conserving treatment is available at participating breast centers throughout the U.S. The Visica 2 Treatment System has FDA clearance for non-cancerous breast tumors (fibroadenomas). Sanarus is currently sponsoring the FROST Clinical Study for early stage breast cancer that does not involve surgical resection. Our team is constantly working to spread awareness of cryoablation as a treatment option throughout the community as well as major breast cancer organizations throughout the country. We understand that patient awareness and physician adoption are both important factors in making cryoablation the standard of care for breast tumors, and are dedicated to making it available to patients seeking an alternative to surgery. www.sanarus.com www.twitter.com/SanarusTech

Website

http://www.sanarus.com

External link for Sanarus Technologies

Industry

Medical Equipment Manufacturing

Company size

11-50 employees

Headquarters

Pleasanton, California

Type

Privately Held

Founded

2009

Specialties

Surgical Alternatives, Cryoablation, Breast Care, Breast Tumors, interventional radiology, radiology, diagnostic imaging, and minimally invasive treatment